Religare Research has recommended a buy rating on Nectar Lifesciences with a target price Rs 503. Nectar is trading at 4.9x FY09E FDEPS of Rs 55.8 and 3.4x FY10E FDEPS of Rs 81.1.
Religare Research has recommended a buy rating on Nectar Lifesciences with a target price Rs 503 in its July 17, 2008 research report. "Amongst the fastest growing Indian pharma companies with a revenue and PAT CAGR of 40% and 52% respectively over FY04–FY08, achieved purely through organic means. Strong presence in the third and fourth generation cephalosporin space and in phytochemicals. Venture into gelatine capsule manufacture and CRAMS to de-risk the business model."
"Nectar is trading at 4.9x FY09E FDEPS of Rs 55.8 and 3.4x FY10E FDEPS of Rs 81.1. Based on its strong growth prospects, leadership in key verticals and transitioning up the high margin value chain, we value the company at 6x FY10E earnings and recommend a Buy with a target price Rs 503," says Religare's research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
For further details click on attachment......
To read the full report click here
Set email alert for
ADS BY GOOGLE
video of the day
Domestic stories attractive; prefer KNR over L&T: HDFC Sec